USPTO serial 85103549
ZIMRALVA
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- NEW APPLICATION PROCESSING
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ZIMRALVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher Serbagi
CHRISTOPHER SERBAGI LAW OFFICES OF CHRISTOPHER SERBAGI488 MADISON AVE STE 1120NEW YORK, NY 10022-5719UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of bacterial infections; diabetes; chronic constipation, irritable bowel syndrome, gastrointestinal motility disorders and other gastrointestinal disorders; pain; neuropathic pain; and central nervous system diseases and disorders, cardiovascular system diseases and disorders, respiratory system diseases and disorders, neurodegenerative diseases and disorders, and neurological diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 18, 2010 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| Aug 18, 2010 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Aug 17, 2010 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Aug 13, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 12, 2010 | NWAP | NEW APPLICATION ENTERED | — |